-
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study J. Chemother. (IF 1.8) Pub Date : 2024-03-18 Hasan Cagri Yildirim, Caner Kapar, Baris Koksal, Mustafa Seyyar, Pervin Can Sanci, Murad Guliyev, Perihan Perkin, Mustafa Buyukkor, Sendag Yaslikaya, Nargiz Majidova, Merve Keskinkilic, Duygu Ozaskin, Tugay Avci, Tugce Kubra Gunes, Murat Arcagok, Alper Topal, Gul Sema Yildiran Keskin, Gozde Kavgaci, Nilgun Yildirim, Ozde Melisa Celayir, Nilufer Avci, Ferit Aslan, Ali Alkan, Mert Erciyestepe, Muhammet
The only phase 3 study on the effectiveness of CDK 4-6 inhibitors in first-line treatment in premenopausal patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer is th...
-
Evaluation of predictors of third-generation cephalosporin non-susceptibility and factors affecting recurrence or death in bacteremia caused by Citrobacter freundii complex, Enterobacter cloacae complex, and Klebsiella aerogenes J. Chemother. (IF 1.8) Pub Date : 2024-03-07 Kazuhiro Kobayashi, Atsuko Hata, Waki Imoto, Shigeki Kakuno, Wataru Shibata, Koichi Yamada, Hiroshi Kawaguchi, Norihiro Sakurai, Toshikazu Ito, Kazuya Uenoyama, Tamotsu Takahashi, Satoru Ueda, Toshiro Katayama, Masahide Onoue, Hiroshi Kakeya
Factors involved in the susceptibility of third-generation cephalosporins (3GCs) to bacteremia caused by Citrobacter freundii complex, Enterobacter cloacae complex, and Klebsiella aerogenes were in...
-
Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability J. Chemother. (IF 1.8) Pub Date : 2024-03-04 Mohamad Abou Chakra, Mohamad Moussa, Michael A. O’Donnell
Published in Journal of Chemotherapy (Ahead of Print, 2024)
-
Antimicrobial dosing recommendations during continuous renal replacement therapy: different databases, different doses J. Chemother. (IF 1.8) Pub Date : 2024-02-26 Aysel Pehlivanli, Tuğba Yanik Yalçin, Fatma İrem Yeşiler, Helin Şahintürk, Özlem Kurt Azap, Pınar Zeyneloğlu, Bilgen Başgut
Meticulous antimicrobial management is essential among critically ill patients with acute kidney injury, particularly if renal replacement therapy is needed. Many factors affect drug removal in pat...
-
Amikacin treatment in urinary tract infection patients: evaluating the risk of acute kidney injury – a retrospective cohort study J. Chemother. (IF 1.8) Pub Date : 2024-02-19 Avner Dagan, Danny Epstein, Ami Neuberger, Jonathan Isenberg
The rise in ESBL-producing and carbapenem-resistant Gram-negative bacterial infections is alarming. Aminoglycosides remain attractive for treating urinary tract infections (UTIs). However, aminogly...
-
Evaluation of in vitro activity of ceftaroline, ceftobiprole and their combination with trimethoprim/sulfamethoxazole against MRSA isolates: a two center study J. Chemother. (IF 1.8) Pub Date : 2024-02-13 Hasan Cenk Mirza, Özlem Öğüç Şanlı
There is an increasing need for new synergistic antimicrobial combinations against multidrug-resistant bacteria. Our objective was to evaluate the activity of ceftaroline, ceftobiprole and their co...
-
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes J. Chemother. (IF 1.8) Pub Date : 2024-02-13 Anil Yıldiz, Ahmet Bilici, Ozgur Acikgoz, Jamshid Hamdard, Pelin Basim, Tansel Cakir, Asli Cakir, Omer Fatih Olmez, Cem Gezen, Ozcan Yildiz
The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemothe...
-
In vitro killing of drug susceptible and multidrug resistant bacteria by amikacin considering pulmonary drug concentrations based on an inhaled formulation J. Chemother. (IF 1.8) Pub Date : 2024-02-10 Joseph M. Blondeau, Leah D. Blondeau, Shantelle D. Fitch
Nosocomial infections with drug resistant bacteria impact morbidity and mortality, length of therapy and stay and the overall cost of treatment. Key pathogens with ventilator associated pneumonia m...
-
Self-assembled redox-responsive BRD4 siRNA nanoparticles: fomulation and its in vitro delivery in gastric cancer cells J. Chemother. (IF 1.8) Pub Date : 2024-01-31 Mengying Zhang, Zhonghua An, Yiming Jiang, Meijiao Wei, Xiangbo Li, Yifan Wang, Hongbo Wang, Yanling Gong
With the development of newer biomarkers in the diagnosis of gastric cancer (GC), therapeutic targets are emerging and molecular-targeted therapy is in progress RNA interference has emerged as a pr...
-
Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer (NSCLC) J. Chemother. (IF 1.8) Pub Date : 2024-02-01 Thierry Landre, Christos Chouaïd, Nassyma Sadaoui, Djamila Bouharati, Chérifa Taleb
Anti-PD-1/PD-L1 plus chemotherapy (CT) is considered the standard of care in first line treatment of metastatic NSCLC. However, the clinical benefit of this combination in older patients is controv...
-
Antihyperlipidemic drug rosuvastatin suppressed tumor progression and potentiated chemosensitivity by downregulating CCNA2 in lung adenocarcinoma J. Chemother. (IF 1.8) Pub Date : 2024-01-30 Xiang-Di Tan, Cui-Fang Luo, Si-Yu Liang
Rosuvastatin (RSV) is widely used to treat hyperlipidemia and hypercholesterolemia and is recommended for the primary and secondary prevention of cardiovascular diseases (CVD). In this study, we ai...
-
Pharmacokinetic parameters of CAZ–AVI in the normal lung and in models of pneumonia: lessons for treatment optimization in critical care J. Chemother. (IF 1.8) Pub Date : 2024-01-30 Sabiha Gul, Raffaella Gallo, Lorenzo Bertolino, Fabian Patauner, Salvatore Buono, Rosanna De Rosa, Clelia Esposito, Nicola Galdieri, Arta Karruli, Domenico Iossa, Eugenio Piscitelli, Roberto Andini, Antonio Corcione, Emanuele Durante-Mangoni
The spread of multidrug-resistant Gram-negative bacterial infections is a significant issue for worldwide public health. Gram-negative organisms regularly develop resistance to antibiotics, especia...
-
The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing J. Chemother. (IF 1.8) Pub Date : 2024-01-23 Osman Köstek, Ahmet Demirel, Muhammet Bekir Hacıoğlu, Didem Tastekin, Senem Karabulut, Abidin Gündogdu, Nadiye Sever, Murat Ayhan, Abdussamed Çelebi, Nargiz Majidova, Alper Yaşar, Yeşim Ağyol, Pınar Erel, Erkam Kocaaslan, Ali Kaan Güren, Rukiye Arıkan, Selver Isık, Ozlem Ercelep, Sema Sezgin Goksu, Celal Alandag, İrem Bilgetekin, Burcu Caner, Ahmet Bilge Sahin, Ahmet Gulmez, Baran Akagunduz, Fatih
The prognosis of patients with advanced HCC can vary widely depending on factors such as the stage of the cancer, the patient’s overall health, and treatment regimens. This study aimed to investiga...
-
Macrolides impact the growth ability of clinical Pseudomonas aeruginosa through quorum-sensing systems J. Chemother. (IF 1.8) Pub Date : 2024-01-23 Katerina Apostolaki, Lazaros A. Gagaletsios, Costas C. Papagiannitsis, Efthimia Petinaki
The aim of the present study was to examine the impact of macrolides on the expression of virulence factors and QS-associated genes in clinical P. aeruginosa isolates. Among 60 clinical P. aerugino...
-
Antibiotic adjuvant activities of quorum sensing signal molecules DSF and BDSF against mature biofilms of Staphylococci J. Chemother. (IF 1.8) Pub Date : 2024-01-23 Merve Bilgin, Sibel Dosler, Gulten Otuk
Among promising antibiofilm compounds, quorum-sensing (QS) molecules that regulate biological processes such as biofilm formation and intra- or interspecies communication appear to be good candidat...
-
Timing of chemotherapy after diagnosis of small cell lung cancer J. Chemother. (IF 1.8) Pub Date : 2024-01-22 Faruk Tas, Akin Ozturk, Kayhan Erturk
Systemic chemotherapy is the backbone of therapeutic management in small cell lung cancer (SCLC) and delay of treatment may lead to adverse patient outcomes. This study was conducted to determine t...
-
Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study J. Chemother. (IF 1.8) Pub Date : 2024-01-19 Xiao-Chen Wei, Yuan-Yuan Guo, Yi Zhang, Yi-Shan Bu, Feng-Ying Zhang
This study aimed to identify the potential factors associated with immune thyroid dysfunction caused by programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in cancer patients. We...
-
Ultrastructural and immunohistochemical insights on the anti-glioma effects of a dual-drug cocktail in an in vivo experimental model J. Chemother. (IF 1.8) Pub Date : 2024-01-19 Indrani Biswas, Daisy Precilla S., Shreyas S. Kuduvalli, Bhavani K., Sivachandran R., Anitha T. S.
Glioma coined as ‘butterfly tumor’ exhibits intense heterogeneity at the molecular and cellular levels. Although, Temozolomide exerted a long-ranging and prevailing therapeutic effect against gliom...
-
A new chemotherapy strategy for advanced hepatocellular carcinoma with exrahepatic metastasis: predictors of long-term survival J. Chemother. (IF 1.8) Pub Date : 2024-01-08 Juxian Sun, Chang Liu, Dandan He, Dafeng Jiang, Shuqun Cheng, Jie Shi
The prognosis of hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM) is extremely poor. This study aimed to identify prognostic factors for systemic chemotherapy of HCC with EHM. Eigh...
-
Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents J. Chemother. (IF 1.8) Pub Date : 2024-01-05 Mohammad Amin Manavi, Mohammad Hosein Fathian Nasab, Razieh Mohammad Jafari, Ahmad Reza Dehpour
Dose-limiting toxicities (DLTs) are severe adverse effects that define the maximum tolerated dose of a cancer drug. In addition to the specific mechanisms of each drug, common contributing factors ...
-
The tumor microenvironment: shaping cancer progression and treatment response J. Chemother. (IF 1.8) Pub Date : 2024-01-05 Sharav A. Desai, Vipul P. Patel, Kunal P. Bhosle, Sandip D. Nagare, Kirti C. Thombare
The tumor microenvironment (TME) plays a crucial role in cancer progression and treatment response. It comprises a complex network of stromal cells, immune cells, extracellular matrix, and blood ve...
-
Statement of Retraction: Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line J. Chemother. (IF 1.8) Pub Date : 2024-01-02
Published in Journal of Chemotherapy (Ahead of Print, 2024)
-
Fixed-dose antiretroviral combinations in children living with human immunodeficiency virus type 1 (HIV-1): a systematic review J. Chemother. (IF 1.8) Pub Date : 2023-12-28 Federica Attaianese, Irene Dalpiaz, Martina Failla, Elisa Pasquali, Luisa Galli, Elena Chiappini
Fixed-Dose antiretroviral Combinations (FDCs) are the most used drug regimes in adult patients with human-immunodeficiency virus 1 infection, since they increase adherence to antiretroviral therapy...
-
Prognostic and immunological values of SKA3 for overall survival in lung adenocarcinoma and its RNA binding protein involved mechanisms J. Chemother. (IF 1.8) Pub Date : 2023-12-26 Yinfeng Gu, Jinjin Li, Hongjun Guan, Changpeng Sun
This article aimed to investigate the correlations among SKA3 expression and prognosis, clinical relevance, tumor immunity, and RNA-binding protein (RBP)-involved mechanisms for overall survival (O...
-
Emerging role of competing endogenous RNA in lung cancer drug resistance J. Chemother. (IF 1.8) Pub Date : 2023-12-20 Shijie Wu, Ting Luo, Xiaoyong Lei, Xiaoyan Yang
Lung cancer remains one of the most common malignant cancers worldwide, and its survival rate is extremely low. Chemotherapy, the mainstay of lung cancer treatment, is not as effective as it could ...
-
Upregulation of apoptotic genes and downregulation of target genes of Sonic Hedgehog signaling pathway in DAOY medulloblastoma cell line treated with arsenic trioxide J. Chemother. (IF 1.8) Pub Date : 2023-12-22 Mehrdad Ghorbanlou, Fatemeh Moradi, Ronak Shabani, Mehdi Mehdizadeh
Sonic hedgehog (SHH) medulloblastoma etiology is associated with the SHH molecular pathway activation at different levels. We investigated the effect of arsenic trioxide as a downstream-level inhib...
-
Impact of a hospital sepsis management protocol on the selection of empirical antibiotics in infectious disease consultations J. Chemother. (IF 1.8) Pub Date : 2023-12-22 Aslı Özden, Büşra Dalgıç, Mervenur Demir, Gülşen Hazırolan, Ömrüm Uzun, Gökhan Metan
It is well-established that Infectious Diseases consultation (IDC) enhances the prognosis of bloodstream infections. However, it is unclear if adoption of an institutional sepsis protocol would lea...
-
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA.1 variant surge J. Chemother. (IF 1.8) Pub Date : 2023-12-14 Claudia Bartalucci, Alessandro Limongelli, Laura Ambra Nicolini, Marta Ponzano, Stefania Tigano, Sara Tita Farinella, Giuliana Carrega, Gemma Malerba, Federica Magnè, Elisa Balletto, Daniele Roberto Giacobbe, Giovanni Riccio, Giovanni Cenderello, Lucia Taramasso, Bianca Bruzzone, Antonio Vena, Antonio Di Biagio, Malgorzata Mikulska, Andrea De Maria, Chiara Dentone, Matteo Bassetti
Among treatment options for Coronavirus disease 2019 (COVID-19), monoclonal antibodies (mAbs) showed to be effective in preventing disease progression, but real-world data during the Omicron varian...
-
Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma J. Chemother. (IF 1.8) Pub Date : 2023-12-11 Emanuele Cencini, Natale Calomino, Anna Sicuranza, Alessandro Gozzetti, Alberto Fabbri, Monica Bocchia
The management of small lymphocytic lymphoma (SLL) as chronic lymphocytic leukemia (CLL) or an indolent non-Hodgkin lymphoma is highly debated. In this single-center, real-life study, 38 SLL patien...
-
The relationship between statin administration timing and survival outcomes in patients with cancer receiving immune checkpoint blockade J. Chemother. (IF 1.8) Pub Date : 2023-12-08 Zihan Wang, Xin Ya See, Cho-Hung Chiang, Yu-Cheng Chang, Yuan Ping Hsia, Cho-Hsien Chiang, Cheng-Ming Peng, Cho-Han Chiang
Statins have been demonstrated to improve outcomes in patients receiving immune checkpoint blockade (ICB). This study aimed to investigate whether the timing of statin administration influences the...
-
Mpox vaccination and treatment: a systematic review J. Chemother. (IF 1.8) Pub Date : 2023-12-09 Arvin Eslami, Shaya Alimoghadam, Sahar Khoshravesh, Mahsa Shirani, Rojina Alimoghadam, Ilad Alavi Darazam
The Human monkeypox virus (mpox) belongs to the Poxviridae family, characterized by double-stranded DNA. A 2022 outbreak, notably prevalent among men who have sex with men, was confirmed by the Wor...
-
MHY446 induces apoptosis via reactive oxygen species-mediated endoplasmic reticulum stress in HCT116 human colorectal cancer cells J. Chemother. (IF 1.8) Pub Date : 2023-12-06 Yu Ra Ahn, Jung Yoon Jang, Yong Jung Kang, Hye Jin Oh, Min Kyung Kang, Dahye Yoon, Hyung Sik Kim, Hyung Ryong Moon, Hae Young Chung, Nam Deuk Kim
This study investigated the potential of a newly synthesized histone deacetylase (HDAC) inhibitor, MHY446, in inducing cell death in HCT116 colorectal cancer cells and compared its activity with th...
-
PFKP is upregulated in 5-fluorouracil-resistant patients and suppresses the antitumor activity of 5-fluorouracil in colorectal cancer in vitro and in vivo J. Chemother. (IF 1.8) Pub Date : 2023-12-03 Lili Deng, Yan Zhao, Wen Liu
As a long-established chemotherapy drug, 5-fluorouracil (5-FU) is widely used to clinically manage colorectal cancer (CRC). However, a substantial portion of patients develop 5-FU resistance at som...
-
Effectiveness of remdesivir-based therapy for moderate COVID-19: comparison of Omicron and other variant phases J. Chemother. (IF 1.8) Pub Date : 2023-12-03 Atsushi Suzuki, Kensuke Fukumitsu, Jun Fukihara, Takuma Katano, Hisashi Kako, Yuri Maeda, Makoto Ishii, Akio Niimi, Kazuyoshi Imaizumi, Etsuro Yamaguchi
Remdesivir is an antiviral drug for the treatment of coronavirus disease 2019 (COVID-19), and the sustained antiviral activity against Omicron variants of severe acute respiratory syndrome coronavi...
-
Advances in MUC1 resistance to chemotherapy in pancreatic cancer. J. Chemother. (IF 1.8) Pub Date : 2023-11-25 Youhao Yao,Daguang Fan
The incidence of pancreatic cancer (PC), a highly fatal malignancy, is increasing every year. Chemotherapy is an important treatment for it in addition to surgery, yet most patients become resistant to chemotherapeutic agents within a few weeks of treatment initiation. MUC1 is a highly glycosylated transmembrane protein, and studies have shown that aberrantly glycosylated overexpression of MUC1 is
-
Correction J. Chemother. (IF 1.8) Pub Date : 2023-11-20
Published in Journal of Chemotherapy (Ahead of Print, 2023)
-
Oritavancin in vitro activity against Gram-positive organisms from European medical centers: a 10-year longitudinal overview from the SENTRY Antimicrobial Surveillance Program (2010–2019) J. Chemother. (IF 1.8) Pub Date : 2023-11-22 M. A. Pfaller, R. E. Mendes, H. S. Sader, M. Castanheira, C. G. Carvalhaes
To assess oritavancin in vitro activity against clinically relevant Gram-positive pathogens in European (EU) hospitals, a total of 51,531 consecutive and unique clinical isolates collected in 2010–...
-
Efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer: a meta-analysis of phase II and III randomized controlled trials J. Chemother. (IF 1.8) Pub Date : 2023-11-17 Wenxia Sun, Jing Li
We conducted a meta-analysis to evaluate the efficacy and safety of veliparib in the treatment of advanced/metastatic breast cancer. Databases were searched for relevant studies till June 2023. Six...
-
Resveratrol suppresses NSCLC cell growth, invasion and migration by mediating Wnt/β-catenin pathway via downregulating SIX4 and SPHK2 J. Chemother. (IF 1.8) Pub Date : 2023-11-15 Xiaolan Wang, Caixia Liu, Jian Wang, Zexiang Tian
Resveratrol (RSV) has been found to have a cancer-suppressing effect in a variety of cancers, including non-small cell lung cancer (NSCLC). Studies have shown that sine oculis homeobox 4 (SIX4) and...
-
Does discontinuing bleomycin due to toxicity increase the risk of lymphoma progression? Real-life data from a homogeneous population of advanced stage Hodgkin lymphoma J. Chemother. (IF 1.8) Pub Date : 2023-11-16 Umut Yılmaz, Güldane Zulfaliyeva, Adnan Nuri Güzelli, Deniz Özmen, Tuğrul Elverdi, Ayşe Salihoğlu, Ahmet Emre Eskazan, Şeniz Öngören, Zafer Başlar, Muhlis Cem Ar
Hodgkin Lymphoma (HL) is often curable with ABVD therapy and improving outcomes is a main goal of ongoing research. Bleomycin-associated pneumonitis (BAPT) is a potentially life-threatening complic...
-
Recent advances in caspase-3, breast cancer, and traditional Chinese medicine: a review J. Chemother. (IF 1.8) Pub Date : 2023-11-07 He Dou, Ping yang Yu, Yu qi Liu, Yue Zhu, Fu cheng Li, You yu Wang, Xing yan Chen, Min Xiao
Caspases (cysteinyl aspartate-specific proteinases) are a group of structurally similar proteases in the cytoplasm that can be involved in cell differentiation, programmed death, proliferation, and...
-
Case series of metastatic breast cancer patients with visceral crisis treated with CDK4/6 inhibitors J. Chemother. (IF 1.8) Pub Date : 2023-11-09 Marissa Meegdes, Marleen G. A. M. van der Velde, Sandra M. E. Geurts, Maartje A. C. E. van Kats, M. Wouter Dercksen, Vivianne C. G. Tjan-Heijnen
There is an ongoing clinical dilemma of how best to treat patients who present themselves with visceral crisis. The time needed to undo the state of visceral crisis is the most relevant outcome for...
-
Effectiveness and safety of a disposable elastomeric continuous infusion pump for outpatient parenteral antimicrobial therapy (OPAT) in a UK setting J. Chemother. (IF 1.8) Pub Date : 2023-11-09 Oyewole Christopher Durojaiye, Joby Cole, Evangelos I. Kritsotakis
We evaluated the effectiveness and safety of continuous antimicrobial infusion using a disposable elastomeric device in an outpatient parenteral antimicrobial therapy (OPAT) setting. We conducted a...
-
Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway J. Chemother. (IF 1.8) Pub Date : 2023-11-02 Fei Mao, Liangkui Gao, Liming Liu, Yuanjia Tang
Pacritinib is an oral medication that inhibits several kinases including JAK2, FLT3, IRAK and STAT3. It has been recently approved to treat patients with thrombocytopenia and myelofibrosis. Studies...
-
Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report J. Chemother. (IF 1.8) Pub Date : 2023-11-01 Qichen Zhang, Peng Xie, Xiaoming Hou, Chengpeng Zhao, Ling Duan, Hui Qiao
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended as a first-line treatment of EGFR-positive non-small cell lung cancer (...
-
Adjuvant chemotherapy for elderly patients with colorectal cancer: a single-centre observational study in Japan J. Chemother. (IF 1.8) Pub Date : 2023-10-25 Kazuaki Okamoto, Hiroaki Nozawa, Shigenobu Emoto, Koji Murono, Kazuhito Sasaki, Soichiro Ishihara
Adjuvant chemotherapy improves the prognosis of patients with colorectal cancer (CRC) following radical resection. The aim of the present study is to review appropriate chemotherapeutic regimens fo...
-
Sorafenib tosylate-loaded nanosuspension: preparation, optimization, and in vitro cytotoxicity study against human HepG2 carcinoma cells J. Chemother. (IF 1.8) Pub Date : 2023-10-25 Harpreet Kaur Khanuja, Rajendra Awasthi, Harish Dureja
This study aimed to optimize nanosuspension of sorafenib tosylate (an anticancer hydrophobic drug molecule) using a central composite design. Nanosuspension was prepared using a nanoprecipitation-u...
-
Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma J. Chemother. (IF 1.8) Pub Date : 2023-10-20 Nour Faqeer, Rawaa Alrabie, Rand Al-Haddadin, Mohammad Ma’koseh
This retrospective study aimed to assess the characteristics and predictors of infusion-related reactions (IRRs) to rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL). The medical recor...
-
Nivolumab-induced Lambert-Eaton myasthenic syndrome: an immune-related adverse event in nonsmall cell lung cancer J. Chemother. (IF 1.8) Pub Date : 2023-10-14 Syed Tabish Rehman, Syeda Mahnoor Azeem, Areeba Akbar, Omer Shafiq, Syed Shehryar Azeem, Shabbir Hussain A. Ali
Nivolumab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody and was the first immune checkpoint inhibitor drug approved for use in advanced non-small cell lung cancer (NSCL...
-
Antibiotic resistance in Campylobacter jejuni and Campylobacter coli: significant contribution of an RND type efflux pump in erythromycin resistance J. Chemother. (IF 1.8) Pub Date : 2023-10-13 Beyza Oncel, Ufuk Hasdemir, Burak Aksu, Spyros Pournaras
In this study, we aimed to determine the antibiotic resistance status of Campylobacter spp. isolated from human infections in our region, including the role of mechanisms involved in erythromycin r...
-
Astaxanthin induces autophagy and apoptosis in murine melanoma B16F10-Nex2 cells and exhibits antitumor activity in vivo J. Chemother. (IF 1.8) Pub Date : 2023-10-06 Fernanda Fernandes Miranda da Cunha, Angela Pedroso Tonon, Fabricio Machado, Luis Rodolpho Travassos, Nathalia Grazzia, João Fernando Possatto, Agnes Kobayashi Calvo de Sant’ana, Rayssa de Mello Lopes, Tiago Rodrigues, Danilo Ciccone Miguel, Fernanda Ramos Gadelha, Denise Costa Arruda
Countless efforts have been made to prevent and suppress the formation and spread of melanoma. Natural astaxanthin (AST; extracted from the alga Haematococcus pluvialis) showed an antitumor effect ...
-
Varicella zoster virus reactivation reported with isatuximab use J. Chemother. (IF 1.8) Pub Date : 2023-10-06 Michelle Nadeau Nguyen, Graça M. Dores, Afrouz Nayernama, S. Christopher Jones
Isatuximab is a CD38-directed antibody indicated for the treatment of relapsed or refractory multiple myeloma. The Division of Pharmacovigilance at the U.S. Food and Drug Administration (FDA) revie...
-
Rapid health technology assessment of the novel endonuclease inhibitor baloxavir for the treatment of influenza J. Chemother. (IF 1.8) Pub Date : 2023-09-28 Guangliang Huang, Yunfei Tian, Wenyan Cui, Xinhui Zhang, Yonghong Zhao, Xiuju Liu
Through a Rapid Health Technology Assessment (RHTA), we evaluated the efficacy, safety and cost-effectiveness of baloxavir in the treatment of influenza, providing the necessary scientific informat...
-
CircAGFG1 absence decreases PKM2 expression to enhance oxaliplatin sensitivity in colorectal cancer in a miR-7-5p-dependent manner J. Chemother. (IF 1.8) Pub Date : 2023-09-10 Jun Chen, Hongwei Wang, Mingsheng Tang
Abstract Circular RNA (circRNA) ArfGAP with FG repeats 1 (circAGFG1) contributes to colorectal cancer (CRC) development. However, whether circAGFG1 regulates the resistance of CRC to oxaliplatin (L-OHP) remains unknown. CircAGFG1, microRNA-7-5p (miR-7-5p) and pyruvate kinase M2 (PKM2) RNA expression were quantified by quantitative real-time polymerase chain reaction. Protein expression was detected
-
Looking for Stenotrophomonas maltophilia treatment: in vitro activity of ceftazidime/avibactam alone and in combination with aztreonam J. Chemother. (IF 1.8) Pub Date : 2023-08-24 Enrica Maddalena Ranieri, Sofia Denicolò, Stefania Stolfa, Lidia Dalfino, Davide Fiore Bavaro, Annalisa Saracino, Luigi Ronga, Raffaele Del Prete, Adriana Mosca
During the Sars-Cov-2 pandemic, Stenotrophomonas maltophilia (S.maltophilia) secondary pulmonary infections have increased, especially in critically ill patients, highlighting the need for new ther...
-
Effect of SARS-CoV-2 vaccination in a vulnerable COVID-19 cohort: a real-life experience in an Italian Hospital J. Chemother. (IF 1.8) Pub Date : 2023-08-23 Chiara Russo, Luca Tagliafico, Laura Labate, Marta Ponzano, Michele Mirabella, Federica Portunato, Carmen Bellezza, Sara Mora, Eleonora Arboscello, Fiammetta Monacelli, Alessio Nencioni, Alessio Signori, Bianca Bruzzone, Mauro Giacomini, Chiara Dentone, Matteo Bassetti
Clinical trials demonstrated that SARS-CoV-2 vaccines reduce COVID-19-related mortality and morbidity. We describe the effect of vaccination on COVID-19-patients admitted at our hospital. Retrospec...
-
Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis J. Chemother. (IF 1.8) Pub Date : 2023-08-20 Lida Wang, Jiwu Song, Xiangming Xiao, Dianfang Li, Tianmeng Liu, Xiaopo He
Abstract Because of lacking of head-to-head comparison between venetoclax and IDH1/IDH2 inhibitors (ivosidenib/enasidenib) for newly diagnosed unfit patients with acute myeloid leukemia (AML), the optimal option for these patients still remains undefined. We searched relevant published reports. Three RCTs with 180 IDH1 mutant and 165 IDH2 mutant patients were identified. Indirect comparison of OS using
-
Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population J. Chemother. (IF 1.8) Pub Date : 2023-08-20 Yuanyuan Li, Ying Zhang, Jinxia Zhao, Jialu Bian, Yinyu Zhao, Xu Hao, Boyu Liu, Lei Hu, Fang Liu, Changqing Yang, Yufei Feng, Lin Huang
Abstract Voriconazole (VRC) displays highly variable pharmacokinetics impacting treatment efficacy and safety. To provide evidence for optimizing VRC therapy regimens, the authors set out to determine the factors impacting VRC steady-state trough concentration (Cmin) in patients with various albumin (Alb) level. A total of 275 blood samples of 120 patients and their clinical characteristics and genotypes
-
Comparative effectiveness of chemotherapy in different histological types of pancreatic cancer: a PSM-based study using the SEER database J. Chemother. (IF 1.8) Pub Date : 2023-08-21 Canhua Luo, Linfeng Fan, Weijian Lun, Miaomiao Ma, Leshi Liang, Changhui Yu
This study aimed to compare the effectiveness of chemotherapy in different histological types of pancreatic cancer using data collected from the Surveillance, Epidemiology, and End Results (SEER) d...
-
Safety of Sotrovimab use in children with COVID-19: an Italian experience J. Chemother. (IF 1.8) Pub Date : 2023-08-21 Elisabetta Venturini, Lara Fusani, Andrea Lo Vecchio, Sara Maria Scarano, Silvia Garazzino, Giulia Pruccoli, Daniele Donà, Laura Lancella, Guido Castelli Gattinara, Luisa Galli
Sotrovimab is a monoclonal antibody approved in adult and adolescents at high risk for COVID-19. Thirty-three children evaluated in five Italian paediatric centres received Sotrovimab infusion and ...